Kee-Young Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kee-Young Shin has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Glenn J. Hanna
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
26 shared publications - Kristine Wong
Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
26 shared publications - Robert I. Haddad
Dana-Farber Cancer Institute, Boston, MA, USA
26 shared publications - Kartik Sehgal
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
25 shared publications - Michael J. Dennis
Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
25 shared publications - Nicole Scarfo
Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
25 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Phase I Trial and Biomarker Analysis of Buparlisib with Weekly Cisplatin and Radiotherapy in High-risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Purpose: To determine the maximum tolerated dose (MTD) of the pan–class I PI3K inhibitor buparlisib (B) in combination with weekly cisplatin and radiotherapy (RT) among patients with locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) and tobacco history. Patients and Methods: Patients with stage III/IV LA-SCCHN [American Joint Committee on Cancer (AJCC), Seventh Edition] and >10 pack-year tobacco use history were enrolled. Patients received B during a 2-week run-in phase and during chemoradiotherapy (CRT) consisting of standard 70 Gy of RT plus weekly cisplatin. An exploratory analysis of genomic sequencing was performed on biopsy specimens. Results: Twenty-three patients were enrolled {n = 17 at the MTD [B 40 mg daily and cisplatin (CDDP) 30 mg/m2/week]}. Ninety-one percent (21/23) had stage IV disease. Human papillomavirus (HPV) was detected in 15 of 18 cases with oral/oropharyngeal disease. The median follow-up was 23 months. Recurrence was detected in five patients among whom four had evaluable tumor samples. Fifty-percent (2/4) of patients with evaluable tumor samples were characterized by activation of the PI3K pathway. In five patients whose disease responded during the 2-week run-in phase with B alone, 3 of 4 with sequencing data showed loss-of-function mutations in either tumor necrosis factor receptor–associated factor 3 (TRAF3) or cylindromatosis lysine deubiquitinase (CYLD). Preclinical studies with mutations in TRAF3 or CYLD modeled via CRISPR/Cas9 knockout in HPV+ SCCHN cells demonstrate that loss of TRAF3 or CYLD may sensitize SCCHN cell lines to PI3K through mechanisms other than blocking the NF-κB pathway. Conclusions: Low-dose B with CRT was feasible and active in this high-risk cohort, although escalation to the standard weekly cisplatin dose of 40 mg/m2 was not possible. Our data suggest that TRAF3/CYLD-mutant SCCHN may be susceptible to PI3K inhibition with B, whereas PI3K pathway activation seemed to be associated with poor outcomes in this limited dataset.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Open AccessPhase I Trial and Biomarker Analysis of Buparlisib with Weekly Cisplatin and Radiotherapy in High-risk Locally Advanced Squamous Cell Cancer of the Head and Neck
Purpose: To determine the maximum tolerated dose (MTD) of the pan–class I PI3K inhibitor buparlisib (B) in combination with weekly cisplatin and radiotherapy (RT) among patients with locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) and tobacco history. Patients and Methods: Patients with stage III/IV LA-SCCHN [American Joint Committee on Cancer (AJCC), Seventh Edition] and >10 pack-year tobacco use history were enrolled. Patients received B during a 2-week run-in phase and during chemoradiotherapy (CRT) consisting of standard 70 Gy of RT plus weekly cisplatin. An exploratory analysis of genomic sequencing was performed on biopsy specimens. Results: Twenty-three patients were enrolled {n = 17 at the MTD [B 40 mg daily and cisplatin (CDDP) 30 mg/m2/week]}. Ninety-one percent (21/23) had stage IV disease. Human papillomavirus (HPV) was detected in 15 of 18 cases with oral/oropharyngeal disease. The median follow-up was 23 months. Recurrence was detected in five patients among whom four had evaluable tumor samples. Fifty-percent (2/4) of patients with evaluable tumor samples were characterized by activation of the PI3K pathway. In five patients whose disease responded during the 2-week run-in phase with B alone, 3 of 4 with sequencing data showed loss-of-function mutations in either tumor necrosis factor receptor–associated factor 3 (TRAF3) or cylindromatosis lysine deubiquitinase (CYLD). Preclinical studies with mutations in TRAF3 or CYLD modeled via CRISPR/Cas9 knockout in HPV+ SCCHN cells demonstrate that loss of TRAF3 or CYLD may sensitize SCCHN cell lines to PI3K through mechanisms other than blocking the NF-κB pathway. Conclusions: Low-dose B with CRT was feasible and active in this high-risk cohort, although escalation to the standard weekly cisplatin dose of 40 mg/m2 was not possible. Our data suggest that TRAF3/CYLD-mutant SCCHN may be susceptible to PI3K inhibition with B, whereas PI3K pathway activation seemed to be associated with poor outcomes in this limited dataset.
- 21 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer
Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease. Experimental Design: 331 plasma samples from 36 patients were collected both preoperatively and postoperatively. We applied MAESTRO-Pool (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) of the Broad Institute and the Oncodetect® V2 test of Exact Sciences, two MAESTRO-based, ultrasensitive, tumor-informed, mutation enrichment sequencing tests, to all samples. Results: With the Oncodetect V2 test, we found 9 of 14 patients (64%) with recurrence and postoperative plasma available tested ctDNA-positive at their first postoperative sample and all 14 patients tested ctDNA-positive for at least one postoperative sample prior to recurrence. ctDNA was detected below the limit of detection for first-generation assays in 59% of all samples in which we detected ctDNA. By tracking a median of 2.1-fold more mutations per patient (up to 5,000 total mutations per patient), the Oncodetect V2 test showed highly concordant results (98.9% positive percent agreement), improved ctDNA detection, and longer lead times to recurrence as compared to MAESTRO-Pool. Conclusion: ctDNA detection after curative-intent therapy for locally advanced esophageal cancer had strong positive and negative predictive values for recurrence. Given the low ctDNA levels observed, and that all patients with recurrence were eventually ctDNA-positive, ctDNA testing in esophageal cancer may benefit from ultrasensitive tests that detect part-per-million levels of ctDNA.
- 21 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer
Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease. Experimental Design: 331 plasma samples from 36 patients were collected both preoperatively and postoperatively. We applied MAESTRO-Pool (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) of the Broad Institute and the Oncodetect® V2 test of Exact Sciences, two MAESTRO-based, ultrasensitive, tumor-informed, mutation enrichment sequencing tests, to all samples. Results: With the Oncodetect V2 test, we found 9 of 14 patients (64%) with recurrence and postoperative plasma available tested ctDNA-positive at their first postoperative sample and all 14 patients tested ctDNA-positive for at least one postoperative sample prior to recurrence. ctDNA was detected below the limit of detection for first-generation assays in 59% of all samples in which we detected ctDNA. By tracking a median of 2.1-fold more mutations per patient (up to 5,000 total mutations per patient), the Oncodetect V2 test showed highly concordant results (98.9% positive percent agreement), improved ctDNA detection, and longer lead times to recurrence as compared to MAESTRO-Pool. Conclusion: ctDNA detection after curative-intent therapy for locally advanced esophageal cancer had strong positive and negative predictive values for recurrence. Given the low ctDNA levels observed, and that all patients with recurrence were eventually ctDNA-positive, ctDNA testing in esophageal cancer may benefit from ultrasensitive tests that detect part-per-million levels of ctDNA.
- 10 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2224-2233
Association between radiographic response and subsequent recurrence in brain metastases treated with radiation: Implications for response assessment criteria
Background: The Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) criteria comprise the foundation for assessment of investigational approaches in brain metastases, including novel radiation-based techniques. We characterized the relationship between RANO-BM response and long-term tumor control, the primary objective of radiation, in patients with brain metastases. Methods: We identified 1454 patients with 4166 newly diagnosed brain metastases managed with radiation therapy between 2008 and 2022. Initial response (progressive disease, stable disease, partial response, or complete response) was assessed per metastasis by RANO-BM criteria. Multivariable Fine and Gray’s competing risk regression identified patient and metastasis-level characteristics, including response, associated with local recurrence. Results: The study population had a median (IQR) of 3 (1-6) brain metastases. Per-metastasis, partial response was most common (n = 1662, 40%), followed by stable disease (n = 1304, 31%), complete response (n = 1023, 25%), and progressive disease (n = 177, 4%). Compared to partial response, complete response was associated with a lower likelihood of local recurrence (hazard ratio [HR] = 0.44, 95% CI: 0.31-0.63, P < .001), whereas stable disease was not (HR = 1.15, 95% CI: 0.91-1.45, P = .25). On subgroup analysis, the association between stable disease vs partial response and local recurrence was modality-dependent, with no difference after whole brain radiation noted but higher recurrence with stable disease after stereotactic radiation observed. Conclusions: In radiotherapeutically managed brain metastases, particularly those treated with whole brain radiation, the association between response and local control is weak, especially among the most common response categories of partial response and stable disease. If validated, trials and guidelines assessing novel radiotherapeutic approaches should focus on long-term local control.
- 10 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2224-2233
Association between radiographic response and subsequent recurrence in brain metastases treated with radiation: Implications for response assessment criteria
Background: The Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) criteria comprise the foundation for assessment of investigational approaches in brain metastases, including novel radiation-based techniques. We characterized the relationship between RANO-BM response and long-term tumor control, the primary objective of radiation, in patients with brain metastases. Methods: We identified 1454 patients with 4166 newly diagnosed brain metastases managed with radiation therapy between 2008 and 2022. Initial response (progressive disease, stable disease, partial response, or complete response) was assessed per metastasis by RANO-BM criteria. Multivariable Fine and Gray’s competing risk regression identified patient and metastasis-level characteristics, including response, associated with local recurrence. Results: The study population had a median (IQR) of 3 (1-6) brain metastases. Per-metastasis, partial response was most common (n = 1662, 40%), followed by stable disease (n = 1304, 31%), complete response (n = 1023, 25%), and progressive disease (n = 177, 4%). Compared to partial response, complete response was associated with a lower likelihood of local recurrence (hazard ratio [HR] = 0.44, 95% CI: 0.31-0.63, P < .001), whereas stable disease was not (HR = 1.15, 95% CI: 0.91-1.45, P = .25). On subgroup analysis, the association between stable disease vs partial response and local recurrence was modality-dependent, with no difference after whole brain radiation noted but higher recurrence with stable disease after stereotactic radiation observed. Conclusions: In radiotherapeutically managed brain metastases, particularly those treated with whole brain radiation, the association between response and local control is weak, especially among the most common response categories of partial response and stable disease. If validated, trials and guidelines assessing novel radiotherapeutic approaches should focus on long-term local control.
- 17 March 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102548
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
- 17 March 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (4) , 102548
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Predictors of Response to Treatment (univariate logistic regression)
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Predictors of Response to Treatment (univariate logistic regression)
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Reasons for Treatment Discontinuation
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Reasons for Treatment Discontinuation
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Purpose:Glycogen synthase kinase 3β (GSK-3β) is a known therapeutic target in cancer. Aberrant nuclear GSK-3β (nGSK-3β) expression has been shown in some salivary gland cancers. Elraglusib is a small-molecule GSK-3β inhibitor with immunomodulatory potential. We hypothesized that elraglusib plus platinum-based chemotherapy and immunotherapy priming would be a novel treatment approach for salivary gland cancer.Patients and Methods:This phase II, open-label trial enrolled patients with recurrent or metastatic salivary gland cancer [adenoid cystic carcinoma (ACC) vs. other subtypes] with disease progression in the preceding year. Cohort 1 received elraglusib (15 mg/kg i.v. on days 1 and 4) plus carboplatin (AUC = 5) or cisplatin (75 mg/m2) every 21 days. Cohort 2 received two cycles of pembrolizumab (200 mg i.v.) every 21 days prior to the same regimen. The primary endpoint included best overall response rate (ORR) by RECIST v1.1 (>5/32 in response to detect 25% ORR).Results:Thirty-two patients were enrolled, including 15 (47%) with ACC and 17 (53%) with non-ACC. The best ORR was 9.4% [3/32; 95% confidence interval (CI), 2–25; three partial responses, all non-ACC]. Nineteen (59%) patients achieved stable disease. The median duration of response was 6.9 months. Common treatment-related adverse events were anemia (22, 69%), nausea (16, 50%), and neutropenia (14, 44%). At the median follow-up of 18.3 months, the median progression-free survival was 6.4 months (95% CI, 2.3–8.8), and the median overall survival was 18.6 months (95% CI, 9.7–29.4) overall. The median nGSK-3β expression was 50% versus 2% for responders versus nonresponders.Conclusions:The trial did not meet its primary endpoint, although 18% of patients with non-ACC treated with immune priming followed by cisplatin plus elraglusib achieved a response. Higher nGSK-3β expression was observed in tumor samples obtained from responders.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Elraglusib, a Glycogen Synthase Kinase 3β Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma
Purpose:Glycogen synthase kinase 3β (GSK-3β) is a known therapeutic target in cancer. Aberrant nuclear GSK-3β (nGSK-3β) expression has been shown in some salivary gland cancers. Elraglusib is a small-molecule GSK-3β inhibitor with immunomodulatory potential. We hypothesized that elraglusib plus platinum-based chemotherapy and immunotherapy priming would be a novel treatment approach for salivary gland cancer.Patients and Methods:This phase II, open-label trial enrolled patients with recurrent or metastatic salivary gland cancer [adenoid cystic carcinoma (ACC) vs. other subtypes] with disease progression in the preceding year. Cohort 1 received elraglusib (15 mg/kg i.v. on days 1 and 4) plus carboplatin (AUC = 5) or cisplatin (75 mg/m2) every 21 days. Cohort 2 received two cycles of pembrolizumab (200 mg i.v.) every 21 days prior to the same regimen. The primary endpoint included best overall response rate (ORR) by RECIST v1.1 (>5/32 in response to detect 25% ORR).Results:Thirty-two patients were enrolled, including 15 (47%) with ACC and 17 (53%) with non-ACC. The best ORR was 9.4% [3/32; 95% confidence interval (CI), 2–25; three partial responses, all non-ACC]. Nineteen (59%) patients achieved stable disease. The median duration of response was 6.9 months. Common treatment-related adverse events were anemia (22, 69%), nausea (16, 50%), and neutropenia (14, 44%). At the median follow-up of 18.3 months, the median progression-free survival was 6.4 months (95% CI, 2.3–8.8), and the median overall survival was 18.6 months (95% CI, 9.7–29.4) overall. The median nGSK-3β expression was 50% versus 2% for responders versus nonresponders.Conclusions:The trial did not meet its primary endpoint, although 18% of patients with non-ACC treated with immune priming followed by cisplatin plus elraglusib achieved a response. Higher nGSK-3β expression was observed in tumor samples obtained from responders.